Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/1999
10/28/1999WO1999053910A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
10/28/1999WO1999053757A1 Autoantigenic fragments, methods and assays
10/28/1999WO1999042839A3 Treating cancer
10/28/1999WO1999042089A9 Use of thiadiazolo[4,3-a]pyridine derivatives
10/28/1999WO1999039740A3 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
10/28/1999WO1999037299B1 Use of inhibitors for the treatment of disorders related to rtk hyperfunction, especially cancer
10/28/1999WO1999036063A9 Vanadium (iv) metallocene complexes having spermicidal activity
10/28/1999WO1999033858A9 Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
10/28/1999WO1999032516A3 Pharmaceutical compositions containing the long pentraxin ptx3
10/28/1999WO1999027080A3 Human protein kinase and kinase inhibitors
10/28/1999WO1999024460B1 Dipeptide nitriles
10/28/1999DE19818802A1 Stable mitoxantron solutions useful for cancer therapy
10/28/1999DE19818620A1 New polypeptides and their nucleic acids, useful for treatment of bladder tumor and identification of therapeutic agents
10/28/1999DE19818619A1 New nucleic acid sequences expressed in bladder tumor tissue, and derived polypeptides, for treatment of bladder tumor and identification of therapeutic agents
10/28/1999DE19818044A1 Reducing side effects or neutralizing action of carcinostatic or immunosuppressive agents, especially pyridine derivatives, using vitamin PP compounds, e.g. nicotinamide
10/28/1999CA2329495A1 Autoantigenic fragments, methods and assays
10/28/1999CA2329413A1 2,3-olefinic epothilone derivatives
10/28/1999CA2328962A1 Btk inhibitors and methods for their identification and use
10/28/1999CA2328720A1 Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
10/28/1999CA2328430A1 Substituted benzamides, their production and their use as cysteine protease inhibitors
10/28/1999CA2326823A1 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/28/1999CA2326685A1 Enhancing immune responses to genetic immunization by using a chemokine
10/28/1999CA2326406A1 Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy
10/28/1999CA2325864A1 Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy
10/28/1999CA2325848A1 B-cell growth factor related protein
10/28/1999CA2325821A1 Antisense oligonucleotides for the inhibition of integrin .alpha.v-subunit expression
10/28/1999CA2325596A1 Combination therapy using nucleic acids and radio therapy
10/28/1999CA2325573A1 A method for inhibiting tumor invasion or spreading in a subject
10/28/1999CA2325561A1 Combination therapy using nucleic acids and conventional drugs
10/28/1999CA2324995A1 Methods and products related to metabolic interactions in disease
10/28/1999CA2324975A1 Isolated nucleic acid molecule encoding cancer associated antigens, the antigens per se, and uses thereof
10/28/1999CA2323609A1 12,13-cyclopropane epothilone derivatives
10/28/1999CA2323571A1 Novel human k+ ion channel and therapeutic applications thereof
10/28/1999CA2269103A1 Peptides binding to bone marrow stromal cell antigen
10/27/1999EP0952218A2 Single chain, multiple antigen-binding molecule, its preparation and use
10/27/1999EP0952213A2 Process for inducing an immune response mediated by NK-cells
10/27/1999EP0952154A2 N-acyl and N-aroyl aralkyl amides
10/27/1999EP0952149A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors
10/27/1999EP0952148A1 Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
10/27/1999EP0951568A1 Methods for detecting and inhibiting the rna component of telomerase
10/27/1999EP0951559A1 Recombinant pox virus for immunization against tumor-associated antigens
10/27/1999EP0951556A2 Disease associated protein tyrosine phosphatases
10/27/1999EP0951553A2 Adenovirus e4 proteins for inducing cell death
10/27/1999EP0951545A2 Human gtp-binding proteins
10/27/1999EP0951542A2 Secreted proteins and polynucleotides encoding them
10/27/1999EP0951540A2 Antisense nucleic acids and hammerhead ribozymes
10/27/1999EP0951484A2 Colon cancer kh-1 and n3 antigens
10/27/1999EP0951478A1 Polysaccharide-peptide derivatives
10/27/1999EP0951471A1 Cycloalkyl inhibitors of protein farnesyltransferase
10/27/1999EP0951467A1 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE
10/27/1999EP0951295A1 Methods and compositions useful for inhibition of angiogenesis
10/27/1999EP0951291A1 Cancer treatment drug
10/27/1999EP0951286A2 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
10/27/1999EP0951285A1 Inhibitors of farnesyl-protein transferase
10/27/1999EP0641785B1 Triazolylated tertiary amine compound or salt thereof
10/27/1999EP0539525B1 Vitaletheine and use in cell culture and therapy
10/27/1999CN1233289A TNF-Beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
10/27/1999CN1233288A GnRH-leukotoxin chimeras
10/27/1999CN1233254A Purine L-nucleosides, analogs and uses thereof
10/27/1999CN1233237A Heteroaryl succinamides and their use as metalloproteinase inhibitors
10/27/1999CN1233185A Nucleosome-based anti-tumor compositions
10/27/1999CN1233177A Therapeutic treatment for VEGF related diseases
10/27/1999CN1233173A Therapeutic methods and compositions involving isoflavones
10/27/1999CN1233171A Inhibition of nuclear transcription factor NF-'kappa' B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin
10/27/1999CN1233169A Process for the manufacture of a pulverous preparation
10/27/1999CN1233150A Method for inhibiting the expression of FAS
10/26/1999US5973163 Oxazolidine carboxylic acid intermediates for esterification of taxanes
10/26/1999US5972982 Containing 5-to 9-membered heteroaryl mono- or bicyclic ring system having no more than 1 carbonyl carbon in the ring system; viricides, bactericides
10/26/1999US5972976 Aminostilbazole derivative and medicine
10/26/1999US5972955 Water soluble C-ring analogues of 20(S)-camptothecin
10/26/1999US5972928 Administering an antigrowth agent
10/26/1999US5972917 Treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders
10/26/1999US5972902 DNA encoding human IL-6 receptor antagonist and protein encoded thereby
10/26/1999US5972896 Antiangiogenic peptides and methods for inhibiting angiogenesis
10/26/1999US5972879 Inhibiting agent against the proliferation of tumor cells
10/26/1999US5972688 HTm4 methods of treatment and assays, agonists and antagonists
10/26/1999US5972676 Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
10/26/1999US5972652 Polynucleotides encoding secreted proteins
10/26/1999US5972649 Polynucleotide sequence encoding human multiple endocrine neoplasia type 1 protein
10/26/1999US5972598 Methods for preventing multidrug resistance in cancer cells
10/26/1999US5972353 Immunogenic amount of an immunologically active mn protein or m polypeptide effective to immunize a vertebrate against a neoplastic disease associated with expression of mn antigen
10/26/1999US5972338 ?tie? or ?tie? are acronyms, which stand for ?tyrosine kinase containing ig and egf homology domains?; present invention concerns novel human tie ligand homologues with powerful effects on vasculature; antitumor agents
10/26/1999US5972337 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
10/26/1999US5972334 Vaccines for treatment of lymphoma and leukemia
10/26/1999US5972308 Reacting technetium-99 with a cyclic oligopeptide having amino acid units containing a mercaptan group attached to the ring through a homocysteine unit.
10/26/1999CA2163118C Aurintricaboxylic acid fractions and analogues with anti-angiogenic activity and methods of use
10/26/1999CA2029678C Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 14
10/26/1999CA1340805C Nucleotide sequence incoding plant ribosome inactivating protein
10/21/1999WO1999053076A1 Tao protein kinases and methods of use therefor
10/21/1999WO1999053061A2 Tumor associated nucleic acids and uses therefor
10/21/1999WO1999053040A2 Human nucleic acid sequences from ovarian tumour tissue
10/21/1999WO1999053036A2 Ste20-related protein kinases
10/21/1999WO1999053026A1 Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
10/21/1999WO1999052925A1 Programmed cell death and caspase-12
10/21/1999WO1999052921A1 13-dihydro-3'aziridino anthracyclines
10/21/1999WO1999052910A1 Bicyclic hydroxamic acid derivatives
10/21/1999WO1999052907A1 Azabicyclic 5ht1 receptor ligands
10/21/1999WO1999052898A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors
10/21/1999WO1999052896A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999WO1999052890A1 Chromanone and thiochromanone derivatives
1 ... 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 ... 2211